A Phase 1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX 2-73 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2014
At a glance
- Drugs ANAVEX 2-73 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Anavex Life Sciences
- 17 Nov 2014 Full results were presented at CNS Summit 2014, according to an Anavex Life Sciences media release.
- 17 Nov 2014 Results published in Anavex Life Sciences media release.
- 14 Nov 2011 Status changed from recruiting to completed.